Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
NuCana plc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies using its proprietary ProTide technology platform. The company operates within the biotechnology and oncology drug development industries, with a strategic emphasis on improving the effectiveness of nucleoside analog-based chemotherapies. NuCana’s core approach is to modify existing cancer drugs to overcome resistance mechanisms and enhance tumor targeting, aiming to improve clinical outcomes compared with standard-of-care treatments.
NuCana’s primary business activity is the research and development of oncology drug candidates, with no approved commercial products as of the most recent public disclosures. Its lead programs have targeted solid tumors, including colorectal, pancreatic, biliary tract, and ovarian cancers. The company was founded in 2017 and is headquartered in Edinburgh, Scotland. NuCana became publicly traded through an initial public offering on the Nasdaq Stock Market in 2017, positioning itself as a transatlantic biotechnology company with operations in both the United Kingdom and the United States.
Business Operations
NuCana’s operations are centered on a single reportable segment: oncology drug discovery and development. The company generates no product revenue and relies primarily on equity financing and cash reserves to fund research, clinical trials, and general corporate activities. Its development pipeline has historically been led by NUC-3373, a ProTide transformation of 5-fluorouracil (5-FU), and NUC-7738, a ProTide of 3′-deoxyadenosine (3′-dA), both designed to bypass cancer cell resistance pathways associated with conventional chemotherapy.
The company conducts clinical trials through a combination of internal management and external partnerships with contract research organizations. NuCana maintains operational infrastructure in both the UK and the US, with clinical development activities primarily conducted internationally. As of the latest publicly available filings, NuCana does not report material revenue from collaborations, licensing agreements, or joint ventures, and its business remains focused on advancing proprietary assets through clinical development stages.
Strategic Position & Investments
NuCana’s strategic direction has been shaped by pipeline prioritization and capital preservation following mixed clinical trial outcomes in recent years. The company has publicly disclosed a focus on evaluating strategic alternatives for its assets, including potential partnerships, out-licensing opportunities, or further internal development depending on available resources. Investment activity has been primarily directed toward clinical trials, regulatory interactions, and intellectual property protection related to its ProTide technology.
The company does not operate as a diversified holding entity and does not report a portfolio of unrelated investments or subsidiaries. Its intellectual property portfolio is a central strategic asset, covering composition of matter and methods of use for its drug candidates. NuCana’s exposure to emerging technologies is largely confined to advances in nucleotide prodrug chemistry and targeted oncology therapeutics rather than broader platform diversification.
Geographic Footprint
NuCana plc is headquartered in Edinburgh, Scotland, with a significant operational presence in the United States, reflecting its Nasdaq listing and investor base. The company’s clinical development activities are conducted across multiple international regions through global clinical trial sites, particularly in North America and Europe.
While NuCana does not maintain commercial operations in Asia-Pacific, Latin America, or Africa, patients in these regions may have participated in multinational clinical trials managed by third-party research organizations. Overall, NuCana’s geographic footprint reflects that of a development-stage biotechnology company with a global clinical reach but limited physical infrastructure outside its core UK and US operations.
Leadership & Governance
NuCana is governed by a board of directors with experience in biotechnology, pharmaceuticals, and capital markets. The company was co-founded by Hugh S. Griffith and Chris Evans, with origins linked to academic research and biotechnology entrepreneurship in the UK. Leadership has emphasized scientific rigor, disciplined capital allocation, and strategic flexibility in response to evolving clinical data.
Key members of the executive leadership team include:
- Hugh S. Griffith – Founder and Executive Chairman
- Chris Evans – Co‑Founder and Non‑Executive Director
- David R. Hung, M.D. – Chief Executive Officer
- James A. Groelinger – Chief Financial Officer
- Stephen J. Frame, Ph.D. – Chief Medical Officer
The leadership team’s stated strategic vision has focused on translating differentiated chemistry into clinically meaningful cancer therapies while managing risk through staged development and ongoing evaluation of strategic alternatives.